Potential Oral DMT Showing Safety and Signs of Efficacy in Phase 1 Trial
FT-4202 — an investigational treatment for sickle cell disease (SCD) — has a favorable safety profile and the expected biological effects, providing preliminary support of efficacy, according to data from an ongoing Phase 1 clinical trial. Forma Therapeutics, which is developing FT-4202, plans to start a global Phase…